Patient-Reported Quality of Life After Intravenous Alteplase for Stroke in the WAKE-UP Trial
Märit Jensen(Universität Hamburg), Christian Gerloff(Universität Hamburg), Ewgenia Barow(Universität Hamburg), Götz Thomalla(Universität Hamburg), Fanny Quandt(Universität Hamburg), Robin Lemmens(VIB-KU Leuven Center for Microbiology), Salvador Pedraza(Hospital Clínic de Barcelona), Bastian Cheng(Universität Hamburg), Vincent Thijs(Florey Institute of Neuroscience and Mental Health), Keith W. Muir(University of Glasgow), Norbert Nighoghossian(Université Claude Bernard Lyon 1), Karl Wegscheider(Universität Hamburg), Susanne Sehner(Lyon 1 Université), Martin Ebinger(Universität Hamburg), Eckhard Schlemm(Defense Information Systems Agency), Jochen B. Fiebach(Pathodiagnostik Berlin), Matthias Endres(German Center for Neurodegenerative Diseases), Claus Z. Simonsen(Universität Hamburg), Florent Boutitie(Université Claude Bernard Lyon 1)
Cited by 9
Related Papers
Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet Neurology|2018|2.8k
Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet Neurology|2018|2k
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
|New England Journal of Medicine|2018|1.3k
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
|New England Journal of Medicine|2019|1k
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
|New England Journal of Medicine|2018|856